Trevi Therapeutics (TRVI) Misses Q3 EPS by 1c

Trevi Therapeutics (NASDAQ: TRVI) reported Q3 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• Bessent: We Make A Market Buying Older Bonds
• EU And Canada Plan Far-reaching Deal To Strengthen Partnership - Bloomberg
• UBS upgrades Lockheed Martin to Buy, sees 26% upside on missile growth